Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints

ABSTRACT: Background: Cardiac symptoms due to postacute inflammatory cardiac involvement affect a broad segment of previously well people with only mild acute coronavirus disease 2019 (COVID-19) illness and without overt structural heart disease. Cardiovascular magnetic resonance (CMR) imaging can...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Valentina O. Puntmann, Dietrich Beitzke, Andreas Kammerlander, Inga Voges, Dominik D. Gabbert, Marcus Doerr, Bishwas Chamling, Biykem Bozkurt, Juan Carlos Kaski, Erica Spatz, Eva Herrmann, Gernot Rohde, Philipp DeLeuw, Lenka Taylor, Christine Windemuth-Kieselbach, Cornelia Harz, Marta Santiuste, Laura Schoeckel, Juliana Hirayama, Peter C. Taylor, Colin Berry, Eike Nagel
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2025-01-01
Rangatū:	Journal of Cardiovascular Magnetic Resonance
Ngā marau:	COVID-19 Myocardial inflammation Microvascular Cardiac magnetic resonance Clinical trial Imaging endpoint
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S1097664724011487
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!